Jaap Verweij - Nanotechnology

Author Information

Jaap Verweij is affiliated with the Department of Medical Oncology at Erasmus University Medical Center in Rotterdam, the Netherlands. His research primarily focuses on oncology, with significant contributions in the areas of chemotherapy, clinical trials, and cancer drug development.

Research Contributions

Jaap Verweij has made substantial contributions to oncology research, as evidenced by his numerous publications over the years. Notably, his work includes studies on the efficacy of various cancer treatments, the principles of chemotherapy, and the innovation in clinical trial design. His research in recent years has also focused on the accessibility of cancer drugs in Europe, the combination of novel inhibitors with established therapies, and the outcomes of neoadjuvant chemotherapy combined with regional hyperthermia in soft tissue sarcomas.

Aliases

Jaap Verweij is also known by the aliases J Verweij and J. Verweij.

Publication and Citation Metrics

Metric	Value
Citation Count	90,328
H-Index	113
Paper Count	838

Publications:

A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation

DOI: 10.1158/1078-0432.CCR-20-4185

Year: 2021

Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe

DOI: 10.3390/cancers12082313

Year: 2020

EDATREXATE VERSUS METHOTREXATE IN HEAD AND NECK SCC 1651

DOI:

Year: 2020

Principles of chemotherapy

DOI: 10.1093/MED/9780198779452.003.0028

Year: 2019

Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics

DOI: 10.1007/s10549-019-05305-w

Year: 2019

Innovation in oncology clinical trial design.

DOI: 10.1016/j.ctrv.2019.01.001

Year: 2019

Abstract ED01-01: Successes and failures of targeted drug development in adult and pediatric sarcomas

DOI: 10.1158/1535-7163.TARG-19-ED01-01

Year: 2019

A randomized Bayesian phase 1 design combining an MPS-1 inhibitor with paclitaxel: A strategy to improve determination of the incremental toxicity of a novel compound over a known backbone therapy.

DOI: 10.1200/JCO.2018.36.15_SUPPL.2537

Year: 2018

Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial

DOI: 10.1001/jamaoncol.2017.4996

Year: 2018

Surrogate endpoints in advanced sarcoma trials: a meta-analysis

DOI: 10.18632/oncotarget.26166

Year: 2018

What are Common Lead-Free Materials?

Why is Nanocircuit Testing Important?

Why is the Nanometer Scale Important in Nanotechnology?

What Role Do Nanotechnology Instruments Play?

What are the Advantages of Using Nanotechnology for Tumor Markers?

What are the Advantages of Using CRISPR and Nanotechnology in Diagnostics?

What are Cryogenic Techniques?

What Are Some Current Research and Developments?

What are the Challenges in Developing Tunable Nanomaterials?

What are the Challenges in Implementing Nanotechnology?

Partnered Content Networks

Relevant Topics